GCIA
KDNY

Gabelli & Co Investment Advisers’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-128,600
Closed -$4.94M – 288
2023
Q2 		$4.94M Buy
+128,600
New +$3.3M 0.83% 32

Gabelli & Co Investment Advisers's KDNY Position: Q3 2023 in Review

Gabelli & Co Investment Advisers sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 128,600 shares — an estimated $4.94M sold.

Gabelli & Co Investment Advisers first reported a position in KDNY in Q2 2023 and held it in 1 quarter. The position peaked at $4.94M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Gabelli & Co Investment Advisers reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 128,600 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $4.94M.
  • Gabelli & Co Investment Advisers first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's Chinook Therapeutics, Inc. Common Stock position peaked at $4.94M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2023, filed 8 Nov 2023.